Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | PI4KA | P42356 | 2/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.49 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | GAPDH | P04406 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | STAT6 | P42226 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL216583 | 0.99 | ADORA1 (0.50) | ADORA1ADORA3ADORA2API4KAPI4K2B | |
| Pyrophosphoric Acid SCHEMBL668584 | 0.95 | ADORA1 (0.52) | ADORA1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL15665475 | 0.89 | ADORA1 (0.52) | ADORA1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL8572697 | 0.88 | ADORA1 (0.38) | ADORA1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL214972 | 0.88 | P2RY1 (0.59) | ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2 | |
| SCHEMBL27971039 | 0.87 | FDPS (0.42) | ADORA1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL13738525 | 0.87 | ADORA1 (0.38) | ADORA1ADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL668586 | 0.84 | P2RX1 (0.59) | ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2 | |
| SCHEMBL15665473 | 0.84 | ADORA2A (0.38) | ADORA1ADORA3ADORA2AADORA2BPDE4D | |
| Cytidine SCHEMBL6689693 | 0.84 | LMNA (0.57) | ADORA1ADORA3ADORA2API4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116773710-A | Kit for covering metabolome and metabolic flow of multiple metabolites and use method | 清华大学 | 2023-09-19 | — | — | CN | claimed |
| CN-115590876-A | Application of adenosine phosphate compound or pharmaceutically acceptable salt thereof in preparation of medicine for treating or preventing osteosarcoma | 青岛大学附属医院（CN） | 2023-01-13 | — | — | CN | claimed |
| US-20220162655-A1 | ENGINEERED BIOSYNTHETIC PATHWAYS FOR PRODUCTION OF L-HOMOCYSTEINE BY FERMENTATION | ZYMERGEN INC. (US) | 2022-05-26 | — | — | US | claimed |
| WO-2020198258-A1 | ENGINEERED BIOSYNTHETIC PATHWAYS FOR PRODUCTION OF L-HOMOCYSTEINE BY FERMENTATION | ZYMERGEN INC. (US) | 2020-10-01 | — | — | WO | claimed |
| US-9823254-B2 | Reversible chemoenzymatic labeling of native and fusion carrier protein motifs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-21 | — | — | US | claimed |
| EP-2548951-B1 | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | PLURISTEM LTD (IL) | 2016-05-04 | — | — | EP | claimed |
| US-20150253335-A1 | REVERSIBLE CHEMOENZYMATIC LABELING OF NATIVE AND FUSION CARRIER PROTEIN MOTIFS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-10 | — | — | US | claimed |
| EP-2626417-B1 | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | PLURISTEM LTD (IL) | 2015-09-02 | — | — | EP | claimed |
| WO-2014043561-A1 | REVERSIBLE CHEMOENZYMATIC LABELING OF NATIVE AND FUSION CARRIER PROTEIN MOTIFS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-20 | — | — | WO | claimed |
| EP-1908842-B1 | PEF-TU expression units | BASF SE (DE) | 2013-09-18 | — | — | EP | claimed |
| US-20070026505-A1 | Amino acid and metabolite biosynthesis | NOVUS INTERNATIONAL, INC. | 2007-02-01 | — | — | US | claimed |
| WO-2007012078-A1 | METHIONINE PRODUCING RECOMBINANT MICROORGANISMS | BASF AG (DE) | 2007-01-25 | — | — | WO | claimed |
| WO-2006138689-A2 | IMPROVED AMINO ACID AND METABOLITE BIOSYNTHESIS | MICROBIA, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| WO-2006017342-A2 | ASSAY METHODS FOR ENZYMES ASSOCIATED WITH SULFATION | Y'S THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| WO-2003098184-A2 | METHOD FOR IDENTIFYING MODULATORS OF SULFOTRANSFERASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-11-27 | — | — | WO | claimed |
| US-6365365-B1 | DRUG SCREENING BY CONTACTING ENZYME ENCODED BY SPECIFIC NUCLEOTIDE SEQUENCE WITH SULFATE SOURCE, ACCEPTOR COMPOUND AND MODULATING AGENTS, THEN MEASURING EFFECT ON ENZYME ACTIVITY; ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-02 | — | — | US | claimed |
| US-5925349-A | ANTIARTHRITIC AGENTS, SKIN DISORDERS, INSULIN DEPENDENT DIABETES, ANTIULCER AGENTS AND WOUND HEALING AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-07-20 | — | — | US | claimed |
| EP-0750511-A4 | TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES AND/OR SULFATION INHIBITOR | UNIV CALIFORNIA (US) | 1999-05-06 | — | — | EP | claimed |
| EP-0750511-A1 | TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES AND/OR SULFATION INHIBITOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-01-02 | — | — | EP | claimed |
| WO-1995024920-A1 | TREATING INFLAMMATION VIA THE ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES AND/OR SULFATION INHIBITOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-09-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150253335-A1 | REVERSIBLE CHEMOENZYMATIC LABELING OF NATIVE AND FUSION CARRIER PROTEIN MOTIFS | PLTP, PCTP, PEBP1 | ADORA1 2970/4885ADORA3 3106/4885ADORA2A 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.